A review of the effect of SGLT2 inhibitors on clinical and glycemic outcomes in hospitalized patients: data from studies that included patients with diabetes.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  HORMONES

• Publication date

  2025-09-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s42000-025-00702-xPMID 40928723
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rates of diabetic ketoacidosis with empagliflozin use during hospitalization for acute heart failure.

  2024cited by this paper
• Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure.

  2024cited by this paper
• Effects of dapagliflozin on cardiac function and short-term prognosis of patients with both acute myocardial infarction and type 2 diabetes mellitus.

  2024cited by this paper
• Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients

  2024cited by this paper
• The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPA-RESPONSE-AHF).

  2023cited by this paper
• Economic Costs of Diabetes in the U.S. in 2022.

  2023cited by this paper
• Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

  2023cited by this paper
• The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study.

  2023cited by this paper
• The effect of Dapagliflozin on renal functions in hospitalized patients with Acute Heart Failure

  2023cited by this paper
• Evaluation of the safety of inpatient empagliflozin in a real-world setting

  2023cited by this paper
• Dapagliflozin for inpatient hyperglycemia in cardiac surgery patients with type 2 diabetes: randomised controlled trial (Dapa-Hospital trial)

  2023cited by this paper
• The epidemiology of ketosis and low bicarbonate concentration in inpatients treated with sodium-glucose linked cotransporter inhibitors or dipeptidyl peptidase-4 inhibitors.

  2023cited by this paper
• Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study

  2023cited by this paper
• Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis

  2023cited by this paper
• Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms

  2023cited by this paper
• Impact of Dapagliflozin Treatment on Serum Sodium Concentrations in Acute Heart Failure

  2023cited by this paper
• Early Initiation of Dapagliflozin during Hospitalization for Acute Heart Failure Is Associated with a Shorter Hospital Stay

  2023cited by this paper
• 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2024.

  2023cited by this paper
• Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study.

  2023cited by this paper
• Evaluation of Inpatient Sodium-Glucose Co-Transporter-2 Inhibitor Use in Patients Hospitalized for Acute Heart Failure.

  2023cited by this paper
• Empagliflozin in acute myocardial infarction: the EMMY trial

  2022cited by this paper
• The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

  2022cited by this paper
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2022cited by this paper
• Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure

  2022cited by this paper
• Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study

  2022cited by this paper
• Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline.

  2022cited by this paper
• Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)

  2022cited by this paper
• Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study

  2022cited by this paper
• Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

  2022cited by this paper
• Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction.

  2022cited by this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.

  2022cited by this paper
• Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure

  2021cited by this paper
• Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure

  2021cited by this paper
• Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure

  2021cited by this paper
• Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

  2021cited by this paper
• Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

  2021cited by this paper
• The comparative epidemiology and outcomes of hospitalized patients treated with SGLT2 or DPP4 inhibitors.

  2021cited by this paper
• The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

  2021cited by this paper
• Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection

  2020cited by this paper
• Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction

  2020cited by this paper
• Dapagliflozin in Patients with Chronic Kidney Disease.

  2020cited by this paper
• Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.

  2020cited by this paper
• Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)

  2020cited by this paper
• The use of sodium‐glucose co‐transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?

  2020cited by this paper
• Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.

  2020cited by this paper
• Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

  2020cited by this paper
• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

  2019cited by this paper
• A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes

  2019cited by this paper
• Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

  2019cited by this paper
• Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

  2019cited by this paper
• Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure

  2019cited by this paper
• Dulaglutide‐combined basal plus correction insulin therapy contributes to ideal glycemic control in non‐critical hospitalized patients

  2019cited by this paper
• "Association of glucose concentrations at hospital discharge with readmissions and mortality: A nationwide cohort study."

  2019cited by this paper
• Dapagliflozin for prednisone‐induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease

  2018cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Mortality Among Hospitalized Patients With Hypoglycemia: Insulin Related and Noninsulin Related

  2017cited by this paper
• Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

  2016cited by this paper
• Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery: GLUCO-CABG Trial

  2015cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Increased Glycemic Variability Is Independently Associated With Length of Stay and Mortality in Noncritically Ill Hospitalized Patients

  2013cited by this paper
• Hypoglycemia and Clinical Outcomes in Patients With Diabetes Hospitalized in the General Ward

  2009cited by this paper
• Economic and clinical impact of inpatient diabetic hypoglycemia.

  2009cited by this paper
• Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

  2005cited by this paper
• Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes.

  2002cited by this paper

• Biologic sex and health differences, diabetes, metabolic syndrome, and cancer.

  2026cites this paper